BIOMAT Database Logo BIOMAT Database Logo

Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis. 2004

Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Department of Laboratory Medicine, University of Washington, Seattle, Washington, USA. limaye@u.washington.edu

BACKGROUND The incidence and impact of cytomegalovirus (CMV) disease that occurs despite CMV prophylaxis among liver transplant recipients have been incompletely defined. METHODS The incidence and risk factors for CMV disease during the first posttransplant year in a cohort of liver transplant recipients who received antiviral prophylaxis with oral ganciclovir were retrospectively analyzed using Cox proportional-hazard regression models. RESULTS CMV disease developed in 19 of 259 recipients (7% [95% confidence interval 0.04-0.11]) at a median of 4.5 months posttransplant, included syndrome (63%) or tissue-invasive disease (37%), and was independently associated with an increased risk of mortality during the first posttransplant year (hazard ratio 14 [95% confidence interval 3.8-54], P=0.0007). The incidence was higher (10/38 [26%] vs. 8/180 [4.5%], P<0.0001) in seronegative recipients (R-) of an organ from a seropositive donor (D+) compared with seropositive (R+) patients, respectively. D+R- status was the only variable significantly associated with CMV disease in multivariate analysis. CONCLUSIONS Late CMV disease develops in a substantial proportion of D+R- recipients after prophylaxis is discontinued, is not accurately predicted by patient factors, and is associated with increased mortality. New strategies to identify D+R- patients at risk and to reduce the incidence and impact of late CMV disease in this group are warranted.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003586 Cytomegalovirus Infections Infection with CYTOMEGALOVIRUS, characterized by enlarged cells bearing intranuclear inclusions. Infection may be in almost any organ, but the salivary glands are the most common site in children, as are the lungs in adults. CMV Inclusion,CMV Inclusions,Congenital CMV Infection,Congenital Cytomegalovirus Infection,Cytomegalic Inclusion Disease,Cytomegalovirus Colitis,Cytomegalovirus Inclusion,Cytomegalovirus Inclusion Disease,Cytomegalovirus Inclusions,Inclusion Disease,Perinatal CMV Infection,Perinatal Cytomegalovirus Infection,Renal Tubular Cytomegalovirus Inclusion,Renal Tubular Cytomegalovirus Inclusions,Salivary Gland Virus Disease,Severe Cytomegalovirus Infection,Severe Cytomegalovirus Infections,Infections, Cytomegalovirus,CMV Infection, Congenital,CMV Infection, Perinatal,Colitis, Cytomegalovirus,Congenital CMV Infections,Congenital Cytomegalovirus Infections,Cytomegalic Inclusion Diseases,Cytomegalovirus Colitides,Cytomegalovirus Inclusion Diseases,Cytomegalovirus Infection,Cytomegalovirus Infection, Congenital,Cytomegalovirus Infection, Perinatal,Cytomegalovirus Infection, Severe,Cytomegalovirus Infections, Severe,Disease, Cytomegalic Inclusion,Disease, Cytomegalovirus Inclusion,Diseases, Cytomegalovirus Inclusion,Inclusion Disease, Cytomegalic,Inclusion Disease, Cytomegalovirus,Inclusion Diseases,Inclusion Diseases, Cytomegalovirus,Inclusion, CMV,Inclusion, Cytomegalovirus,Infection, Congenital CMV,Infection, Congenital Cytomegalovirus,Infection, Cytomegalovirus,Infection, Perinatal CMV,Infection, Perinatal Cytomegalovirus,Infection, Severe Cytomegalovirus,Perinatal CMV Infections,Perinatal Cytomegalovirus Infections
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015774 Ganciclovir An ACYCLOVIR analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. BIOLF-62,BW-759,Cytovene,Ganciclovir Sodium,Ganciclovir, Monosodium Salt,Gancyclovir,RS-21592

Related Publications

Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Frequent occult infection with Cytomegalovirus in cardiac transplant recipients despite antiviral prophylaxis.
June 2007, Journal of clinical microbiology,
Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
June 2011, Transplant infectious disease : an official journal of the Transplantation Society,
Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients.
January 2016, Transplantation,
Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Reduction in late onset cytomegalovirus primary disease after discontinuation of antiviral prophylaxis in kidney transplant recipients treated with de novo everolimus.
April 2018, Transplant infectious disease : an official journal of the Transplantation Society,
Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.
June 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons,
Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis.
June 2023, JHEP reports : innovation in hepatology,
Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Cytomegalovirus disease in liver transplant recipients: impact of acyclovir prophylaxis.
June 1993, Transplantation proceedings,
Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Acyclovir prophylaxis for cytomegalovirus in liver transplant recipients.
June 1994, The Journal of infectious diseases,
Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence.
March 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Ajit P Limaye, and Ramaswamy Bakthavatsalam, and Hyung W Kim, and Christian S Kuhr, and Jeffrey B Halldorson, and Patrick J Healey, and Michael Boeckh
Preemptive Therapy vs Antiviral Prophylaxis in Cytomegalovirus-Seronegative Liver Transplant Recipients With Seropositive Donors.
September 2020, JAMA,
Copied contents to your clipboard!